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2 
Abstract 1 
2 
Metastasis of cancer cells to distant organ systems is a complex process that is initiated with 3 
the programming of cells in the primary tumor.  The formation of distant metastatic foci is correlated 4 
with poor prognosis and limited effective treatment options.  We and others have correlated Mouse 5 
double minute 2 (Mdm2) with metastasis; however, the mechanisms involved have not been 6 
elucidated.  Here it is reported that shRNA-mediated silencing of Mdm2 inhibits epithelial-7 
mesenchymal transition (EMT) and cell migration.  In vivo analysis demonstrates that silencing Mdm2 8 
in both post-EMT and basal/ triple negative breast cancers resulted in decreased primary tumor 9 
vasculature, circulating tumor cells, and metastatic lung foci.  Combined, these results demonstrate 10 
the importance of Mdm2 in orchestrating the initial stages of migration and metastasis.  11 
12 
Implications: Mdm2 is the major factor in the initiation of metastasis. 13 
14 
15 
16 
Introduction 17 
18 
Metastatic foci arise after primary tumor cells successfully transition through various phases of 19 
the metastatic process.  These phases include invasive migration from the primary tumor, 20 
intravasation into the blood stream, extravasation into a distant organ, and colonization in conducive 21 
tissues.  In response to avascular hypoxic conditions, primary tumor cells may produce vascular 22 
endothelial growth factor (VEGF), which stimulates angiogenesis, recruits endothelial cells for 23 
neovascularization, and/or permeabilizes existing vasculature through which tumor cells can 24 
intravasate.  The dissemination of tumor cells to distant organs can be initiated through an 25 
3 
intracellular program called epithelial-mesenchymal-transition (EMT).  The programming of tumor 1 
cells to migrate requires the upregulation of transcription factors such as Snail Family Zinc Finger 1 2 
(SNAI1), and increased levels of adhesion proteins and filaments including N-cadherin and vimentin.  3 
Conversely, E-cadherin is decreased as cells transition into a mesenchymal phenotype.  Moreover, 4 
we have shown that the oncogene Mouse Double Minute 2 (Mdm2) is also positively correlated with 5 
EMT (1-5).  Clinically, mdm2 gene amplification occurs in approximately 10% of all human cancers, 6 
yet more importantly, several studies have detected the Mdm2 protein in 40-80% of high-grade 7 
human tumors (6,7).  Increased levels of Mdm2 are correlated with poor prognosis, especially in 8 
breast cancer (8), and several correlative studies have inferred its involvement in metastasis (9-12).  9 
Similarly, we have previously shown that Mdm2 is elevated in 73% of breast carcinomas with known 10 
metastases (1).   11 
Although several reports have asserted that Mdm2 promotes metastasis, they were either 12 
correlative studies using human patient samples (9,10,12), or in vitro studies with or without a 13 
correlative component (1,3-5).  Only two studies thus far have explored the importance of Mdm2 in 14 
metastasis in vivo.  One study, conducted in pancreatic carcinoma cells, found that silencing Mdm2 15 
resulted in decreased proliferation (2).  This study, along with another that used tail vein injection of 16 
transiently transfected KHT-C murine cells (11), employed approaches that did not directly assess the 17 
initiation or other phases of metastasis to define the role of Mdm2.  The authors of both studies 18 
attributed the differences in metastasis to the ability of Mdm2 to downregulate wild type p53.  Early 19 
reports show that Mdm2 can facilitate the destabilization of p53 in response to genotoxic stress, 20 
however, 20-40% of breast cancers subtypes (13), and 80% of basal like breast cancers (14) 21 
maintain mutant p53 (mutp53).  Considering the gain-of-function properties of mutant p53, it might be 22 
expected that any downregulation of mutant p53 would result in decreased metastasis.  Regardless, 23 
unlike p53, mutp53 is unableto induce mdm2 gene expression. We recently demonstrated that the 24 
TGFß1-Smad3/4 axis transcriptionally activates the mdm2 gene independently of p53.  Furthermore, 25 
4 
the activated TGFß1 pathway and elevated Mdm2 levels were correlated with human 1 
invasive/metastatic breast cancer specimens (1).  Here we show that Mdm2 is necessary for 2 
upregulating essential markers of EMT, and consequently migration/ invasion.  Additionally, we show 3 
that Mdm2 is important in upregulating MMP-2 (Matrix Metalloproteinase 2), an indicator of highly 4 
metastatic cancers that colonize the lung.  Our orthotopic experiments show that Mdm2 is a key 5 
mediator of metastatic lung foci through regulation of angiogenesis and intravasation.  These events 6 
are independent of mutp53 and demonstrate a distinct role for Mdm2 at specific stages of the 7 
metastatic process.   8 
9 
MATERIAL AND METHODS 10 
Cell lines, culture conditions, induction of EMT and western blotting 11 
shMdm2 was obtained in pLKO from open biosystems (TRCN0000003380 which targets exon 12 
12). Additional cell lines expressing shMdm2 constructs (TRCN0000003376 and TRCN0000003377) 13 
were also examined to confirm the phenotypes were due to knockdown of Mdm2. Previously 14 
described vectors include shp53 (15,16), MCHERRY (17), and EGFP (17).  Lentivirus was produced 15 
as previously described (16).  Briefly, Lentiviral vectors were packaged in 293T cells using second-16 
generation packaging constructs: pCMV- dR8.74 and pMD2G.  Supernatant media containing virus 17 
were collected at 36 to 48 h, supplemented with 4 μg/mL polybrene, filtered through a 0.45-μm filter, 18 
and added to MDA-MB-468 (R273H p53) and TMD231 cells (a derivative of MDA-MB-231 cells which 19 
metastasize to the lung (18) and have R280K p53).  Cells were selected for puromycin (2 μg/ml) 20 
resistance.  All cells were grown as described (1).  Cells were incubated under normoxia (21% 21 
oxygen in complete DMEM), hypoxia (1% oxygen in complete DMEM/F-12 1:1 HyClone), and/or with 22 
10ng/ml TGFß1 for the times indicated.  Western blot analysis was performed as described by 23 
Waning et al (19) using antibodies: Mdm2 [IF2 (Ab-1; OP46), and 4B2 (OP145) from CalBiochem and 24 
2A10 (ab16895) from Abcam; N-Cadherin (610920) from BDBioSci]; p53 (DO-1; sc-126), GAPDH 25 
5 
(6C5; sc-32233), Vinculin (N-19; sc-7649 or E1E9V-13901p from cell signaling), E-Cadherin (G-10; 1 
sc-8426 and 67A4; sc-2179), Vimentin (RV202; sc-32322), VEGF (147; sc-507), Tubulin (TU-02; sc-2 
8035), and PAI (H-135-sc-8979) from Santa Cruz Biotechnology; Snail (F.31.8- MA5-14801 from 3 
ThermoSci); Actin (A1978) Sigma; HIF1? (NBP1-02160) from Novus and MMP2 (MAB-3308) from 4 
Millipore.  5 
Cell line verification: all cells were tested for mycoplasma with the Mycoplasma Detection Kit 6 
(InvivoGen) during the experiments and before injection into animals; TMD231 cells have a 7 
mesenchymal morphology and MDA-MB-468 have a epithelial-like morphology which was verified by 8 
microscopy. Molecularly, TMD231 do not express E-Cadherin, and MDA-MB-468 express E-Cadherin 9 
which are verified by western blot analysis. The TMD231 cells were generated in-house from MDA-10 
MB-231 cells by Dr. Nakshatri. MDA-MB-468 cells were obtained from ATCC. All cells were passaged 11 
for no more than 3 months between thawing and use in experiments. 12 
13 
Wound healing and invasion assays 14 
Migration of MDA468 cells were assessed using culture inserts (IBIDI) according to 15 
manufacturer’s instructions.  Briefly, 2.45x104 MDA468 shControl cells and 4.9x104 MDA468 shMdm2 16 
cells were placed into both wells of the culture insert (separate insert for each cell line).  After a 48 h 17 
incubation, inserts were removed and images were obtained at the indicated time points.  Gap area 18 
was quantified using the wound healing tool for image J (http://dev.mri.cnrs.fr/projects/imagej-19 
macros/wiki/Wound_Healing_Tool).  Inserts were manufactured to result in a 500 ?m gap.  Time 0 h 20 
was imaged at 5X magnification, and all subsequent time points were imaged at 10X magnification. 21 
TMD231 mCherry shControl and GFP shMdm2 cells were plated onto coverslips in a 35 mm 22 
plate (64,000 cells/plate).  Coverslips were then transferred to a 60 mm plate and secured with 23 
paramount the next day.  Images were obtained immediately and at the times indicated; the number 24 
6 
of cells of each color in three separate fields of view were counted and averaged.   1 
Boyden chamber assays were conducted with BD Matrigel Invasion chamber 8.0 Micron pore 2 
size according to manufacturer’s instruction.  Briefly, 2.5x104 cells were seeded into each well of 3 
matrigel chambers with 5% serum used as the chemoattractant.  After a 22 h incubation under normal 4 
growth conditions, the media was removed and the surface of the membrane was wiped with a cotton 5 
tip swab to remove non-invading cells.  Membranes were then removed from the chambers and 6 
stained by incubating in methanol for 2 min and then 1% toludine blue for 2 min.  Cells were counted 7 
in three random fields at a magnification of 20X and the experiment was done in triplicate.  Percent 8 
invasion was calculated by dividing the mean number of cells invading through the matrigel insert 9 
membrane by the mean number of cells migrating through the control insert membrane. 10 
11 
Orthotopic implantation in mice and assessment 12 
All animal studies have been approved by Indiana University School of Medicine IACUC 13 
(protocol #11190) and were performed by the Indiana University In Vivo Therapeutics Core.  7.5x10514 
TMD 231 shGFP, or shMdm2 cells or 1x106 MDA468 shControl or shMdm2 cells were injected into 15 
the fourth mammary fat pad of NOD-SCID Gamma mice (n=7 per group) obtained from the In Vivo 16 
Therapeutics Core of the Indiana University Simon Cancer Center.  Tumor growth was calculated by 17 
volumetric analysis using calipers.  Tumors were allowed to grow to an average volume of 600 mm3 18 
(TMD231 and MDA468 shControl), 200mm3 (MDA468 shMdm2), or 900 mm3 (TMD231 in the shp53 19 
experiment).   20 
21 
Circulating tumor cell analysis 22 
Cardiac punctures with 1ml TB syringe and a 27G x ½ needle (BD Biosciences) were 23 
performed at necropsy and temporarily stored in vacutainers coated with sodium heparin (BD 24 
7 
Biosciences) prior to peripheral blood mononuclear cells (PBMC) processing.  PBMCs were isolated 1 
by Ficoll-paqueTM Plus (GE Healthcare) separation and cells were stained with 1?g phycoerythrin 2 
(PE) conjugated mouse anti-human EGF Receptor antibody (#555997; BD Pharmigen) per 1x 1063 
cells.  FACS analysis was conducted and data analysis was performed using FlowJo 10.0.8r1.  The 4 
percentage of CTC population of each shControl and shMdm2 sample was determined by positive 5 
human-specific EGFR staining of CTCs in mouse blood.  6 
7 
Tissue Processing and Immunostaining 8 
Tissues were fixed overnight at room temperature in 10% neutral buffered formalin after which 9 
they were transferred through graded concentrations of alcohol to xylene inside a Leica Automated 10 
Vacuum Tissue Processor.  Samples were embedded in paraffin before being cut into five micron 11 
thick sections, mounted onto positively charged slides, and baked at 60 °C.   12 
The Indiana University Pathology Core performed all tumor preparation, hematoxylin & eosin 13 
(H&E) and CD31 staining, and quantitation.  Slides were then deparaffinized in xylene and rehydrated 14 
through graded alcohols to water.  Antigen retrieval was performed by immersing the slides in Target 15 
Retrieval Solution (DAKO) for 20 min at 90 °C, cooling at room temperature for 10 min., washing in 16 
water and then proceeding with immunostaining.  Slides were blocked with protein blocking solution 17 
(Dako) for 30 minutes.  All subsequent staining steps were performed using the Dako FLEX SYSTEM 18 
on an automated Immunostainer; incubations were done at room temperature and Tris buffered 19 
saline plus 0.05% Tween 20, pH 7.4 (TBS - Dako Corp.) was used for all washes and diluents.  20 
Thorough washing was performed after each incubation.  Standard H&E staining was then performed.  21 
Alternatively, slides were stained with anti-mouse CD31 (DIA 310; Dianova).  Control sections were 22 
treated with an isotype control using the same concentration as primary antibodies to verify the 23 
staining specificity. 24 
25 
8 
1 
Image Capturing 2 
Aperio’s whole slide digital imaging system, ScanScope CS, was used for imaging (360 Park 3 
Center Drive Vista, CA 92081).  All slides were imaged at 20x.  Digital images were obtained using 4 
Aperio’s software, ImageScope.  For CD31 analysis, whole primary tumor cross sections were 5 
analyzed, with the exception of the excluded necrotic tissue.  Vessels less than 125 ?m and/or having 6 
a diameter less than 30 ?m were considered immature.  Data from 5 independent hand counts per 7 
tumor were confirmed by a pathologist, averaged and presented as the average percent of immature 8 
vessels (the average number of immature vessels divided by the average total vessels in each 9 
primary tumor).   10 
Lung Metastases Quantification 11 
H&E evaluation of lung metastases was performed by a Pathologic Assistant.  All hand counts 12 
matched Pathological Reads performed by a board certified pathologist.  Metastases from all lungs 13 
were classified as Small (1-25 cells), Medium (26-100 cells), Large (101-500 cells), or Very Large 14 
(501+).  Represented values are averages from each corresponding metastatic size group.   15 
The entire lung of each mouse was scored for metastases and divided by the area of each lung.   16 
17 
18 
Results: 19 
The EMT program is regulated by Mdm2   20 
To confirm that Mdm2 is required for metastasis, MDA468 and TMD231 cells were transduced 21 
with control and Mdm2-specific shRNA lentiviruses.  MDA468 cells, a basal–like cell line, can 22 
undergo EMT while TMD231 cells, a derivative of MDA231 cells, are post-EMT and resemble 23 
mesenchymal cells.  Once the cell lines were confirmed for decreased levels of Mdm2 (Fig. 1a and 24 
Fig.S1), we analyzed levels of mutp53 since Mdm2 can regulate p53 and many studies have 25 
9 
demonstrated that mutp53 promotes tumorigenesis and metastasis (20-38).  Interestingly, knock-1 
down of Mdm2 in the MDA468 cells resulted in an increase in mutp53 levels, while no discernable 2 
difference was observed when TMD231 shMdm2 and shControl cells were compared (Fig. 1a).  We 3 
next explored whether shMdm2 cell lines would undergo EMT.  The mesenchymal marker, SNAI1, 4 
was decreased in both shMdm2 cell lines (Fig. 1b).  EMT markers in shControl and shMdm2 MDA468 5 
cells were further examined and shMdm2 cells were found to molecularly resemble epithelial cells 6 
with regards to E-Cadherin, N-Cadherin, and vimentin (Fig. 1c and Fig.S1).  Silencing Mdm2 also 7 
resulted in a more epithelial-like morphology compared to the shControl cells (Fig, 1d), which is 8 
consistent with the low level of EMT markers.  MDA468 cells were treated with TGFβ1 and hypoxia to 9 
induce EMT.  While TGFβ1 treatment of shControl cells resulted in increased levels of various 10 
mesenchymal markers and a more mesenchymal morphology, it did not affect the markers or alter 11 
the epithelial-like morphology of shMdm2 cells.  TGFβ1 treatment of TMD231 cells did not cause 12 
EMT as these cells are morphologically (spindle-shaped) and molecularly (no E-Cadherin, high snail, 13 
vimentin, N- cadherin) mesenchymal-like (Fig. S1).  Interestingly, despite having increased mutp53 14 
levels, shMdm2 MDA468 cells did not have a mesenchymal phenotype, suggesting a mutant p53-15 
independent role for Mdm2 in EMT.  Taken together, these results indicate that Mdm2 plays an 16 
important role in regulating key intracellular programing for EMT.   17 
18 
Migration and invasion are impaired in cells with decreased Mdm2 19 
20 
Since migration is coupled with EMT, we tested whether Mdm2 affected cellular migration.  21 
Initially, we conducted traditional wound healing assays and quantified gap closure (Fig. 2a).  Gap 22 
closure was dramatically delayed in shMdm2 MDA468 cells (50% at 70h) compared to shControl cells 23 
(completed at 40h).  To confirm these data, we also conducted a slight variation of the wound healing 24 
assay by examining the migration of fluorescent cells off of coverslips.  A GFP- shMdm2 plated 25 
10 
coverslip and a mCherry shControl plated coverslip were transferred and fixed on a new plate.  Cells 1 
that migrated into the void between the coverslips were then counted.  This latter technique allowed 2 
us to compare shMdm2 cells and shControl cells under the same conditions.  shControl cells were 3 
more effective at migration than shMdm2 cells (Fig. 2b).  Lastly, using a Boyden Chamber assay we 4 
demonstrated that shControl cells were able to invade through matrigel more effectively than shMdm2 5 
cells (Fig. 2c).  Thus, using three independent methods, our results show that migration and invasion 6 
are diminished with decreased Mdm2.   7 
8 
MDA468 and TMD231 shMdm2 cells have delayed tumor growth 9 
10 
     Since cell growth and migration can be inter-related, and shMdm2 cells exhibit a defect in 11 
migration, we performed cell cycle analysis by Fluorescence-Activated Cell Sorting (FACS).  12 
Interestingly, while both cell lines have mutp53 (elevated in shMdm2 MDA468), there were no 13 
differences in cell cycle distribution between shControl and shMdm2 (Table S1).  These data 14 
eliminate the role of Mdm2 in regulating gain of function mutp53 in cell cycle and migration.  To 15 
garner insight into the role of Mdm2 in in vivo tumor growth, we orthotopically injected shControl or 16 
shMdm2 MDA468 or TMD231 into the mammary fat pad of 6 week old NSG female mice (n=7 for 17 
each group).  The average tumor volumes and weights of shMdm2 MDA468 tumors were lower than 18 
shControl tumors (Fig. 3a and 3b left panels), despite allowing them to develop for 30 days longer.  19 
This result is notable because mutp53 is thought to enhance tumorigenicity, and its levels are higher 20 
in the shMdm2 MDA468 cell line.  There were no significant differences between the final TMD231 21 
tumor volumes or weight at the time of euthanasia (Fig. 3a and 3b, right panels).  22 
23 
Mdm2 promotes vascularization  24 
25 
11 
1 
examined in vitro levels of key factors associated with angiogenesis.  We and others have shown that 2 
Mdm2 can play a role in stabilizing Hypoxia Inducible Factor 1? (HIF1?) and up-regulating VEGF (39-3 
41).  Mdm2 can also stabilize VEGF mRNA levels to promote angiogenesis (42).  In accordance with 4 
these published findings, there was a substantial decrease in the levels of HIF1? and VEGF in both 5 
the cultured TMD231 and MDA468 lines grown under normoxia or hypoxia when Mdm2 was 6 
knocked-down compared to the shControl (Fig. 4a).  Based on these in vitro results, primary tumors 7 
were sectioned and the endothelial cells were stained with cluster of differentiation 31 (CD31).  In the 8 
presence of Mdm2, the percentage of newly formed, immature vessels in both MDA468 and TMD231 9 
shControl tumors was significantly higher than shMdm2 tumors (Fig. 4b). We next analyzed lysates 10 
from MDA468 and TMD231 shMdm2 tumor sets to confirm the in vitro results.  In agreement with the 11 
levels seen in cell culture (Fig.4a), Fig. 4c demonstrates diminished HIF1? and VEGF levels in 12 
shMdm2 tumors compared to shControl tumors.  Taken together, our in vitro and in vivo data are 13 
congruent in showing that Mdm2 is integrated into the angiogenesis pathway.   14 
While our data suggest Mdm2 is an important driver of angiogenesis, previous reports 15 
implicate mutp53 is also important for this phenomenon (27 ,43-45).  Considering that our cells 16 
maintain mutp53, we tested the importance of this protein in angiogenesis by implanting TMD231 17 
cells that had been transduced with either shControl or shp53 plasmid (Fig. S2).  Surprisingly, shp53 18 
tumors had a significantly higher percentage of immature vessels compared to shControl tumors (Fig. 19 
4b). Analysis of tumor extracts revealed that Mdm2 levels were slightly elevated in shp53 tumors (Fig. 20 
S2).  Thus, Mdm2 promotes vascularization of the tumor via regulation of the HIF1α-VEGF axis and 21 
possibly permits intravasation of tumor cells into the blood stream. 22 
23 
Abrogation of Mdm2 results in diminished Metastasis 24 
25 
Considering the delay in tumor growth in both TMD231 and MDA468 shMdm2 cells, we 
12 
Tumor cells undergo intracellular reprograming to signal for cellular migration.  To assess if 1 
these changes were evident in our in vivo metastasis models we examined EMT markers from 2 
shMdm2 MDA468 tumor extracts.  The results support our in vitro findings of decreased levels of N-3 
Cadherin and SNAI1, and increased levels of E- Cadherin compared to the shControl tumors (Fig. 5a). 4 
Two additional proteins that are associated with metastasis,  Plasminogen Activator Inhibitor-1 (PAI-5 
1), an important tumor angiogenic factor involved in metastasis (46), and Matrix Metalloproteinase-2 6 
(MMP2), a protein that acts to break down extracellular matrix and is associated with metastatic lung 7 
foci (47) were examined by western blot analysis of tumor extracts.  Both PAI-1 and MMP2 were 8 
found to be decreased in shMdm2 primary tumors (Fig. 5a).  9 
These data indicate that the tumors cells are primed to intravaste and, with our angiogenesis 10 
data in Figure 4, suggest that shControl tumor cells would enter into the blood stream.  We extracted 11 
blood from the euthanized animals harboring shControl and shMdm2 tumors, and stained for human 12 
EGFR to detect circulating tumor cells (CTC) by FACS analysis.  We found a greater than four-fold 13 
increase in CTC in animals implanted with MDA468 shControl cells compared to those implanted with 14 
the shMdm2 cells (Fig. 5b).  Conversely, a greater number of shp53 CTC versus shControl CTC was 15 
observed.  This result is in accordance with the vasculature data shown in Figure 4, but contradicts 16 
published findings that suggest mutant p53 is driving metastasis (20-23,25-37,48-50).  Thus, in the 17 
presence of Mdm2, tumor cells are priming the vasculature and entering the blood stream.   18 
After establishing that the numbers of tumor cells entering the blood stream was dependent on 19 
Mdm2, we determined if a corresponding change in lung metastatic foci was evident.  MDA468 20 
shControl cells readily metastasized to the lung with an average of 1 foci/mm2, while the shMdm2 21 
cells averaged only 0.15 foci in the same area.  When Mdm2 was silenced, an 85% decrease in lung 22 
foci was observed even with elevated mutp53 (Fig. 5c top).  Similarly, the TMD231 shControl cells 23 
were significantly more likely to metastasize to the lung than shMdm2 cells (Fig. 5c middle).  24 
Surprisingly, considering the higher number of CTC in shp53 TMD231 cells, there were less 25 
13 
metastatic foci in the lungs compared to control animals (P=0.0046) (Fig. 5c bottom).  These results 1 
are supported by the majority of publications implicating a role for mutp53 in metastasis (20-23,25-2 
37,48-50); however, mutp53 is dispensible for metastatic initiation which requires Mdm2. 3 
4 
Discussion:  5 
6 
Here, we demonstrate that Mdm2 is extremely important in breast cancer metastases to the 7 
lung.  Specifically, we show that Mdm2 is important to promote cancer invasiveness via cell migration, 8 
angiogenesis, and intravasation (Fig. 6).  Molecularly, Mdm2 stabilizes HIF1? which increases VEGF 9 
and transcription factors associated with intracellular metastatic programming (such as SNAI1)(11).  10 
This intracellular pathway increases angiogenesis, and the decrease of vasculature observed with 11 
decreased Mdm2 provides one possible explanation for the small tumor size in the MDA468 shMdm2 12 
tumors as well as the delay in tumor growth of TMD231 shMdm2 tumors.  Therefore, the abundance 13 
of CTC, and lung metastatic foci is reliant on the presence of Mdm2.  Several studies have reported a 14 
role for Mdm2 in migration or EMT in vitro. In contrast, our experiments were conducted in vivo, which 15 
is significant in light of recent publications delineating the importance of the microenvironment in 16 
tumor growth and invasion.  17 
In addition to being essential in early metastasis, Mdm2 may also be important in later stages 18 
as well. While extravasation and colonization was not directly assessed, at least one study has shown 19 
that tail vein injection (bypassing the initial stages of metastasis) of transiently overexpressing Mdm2 20 
in murine cells results in increased metastatic potential. This suggests that Mdm2 may have a role in 21 
extravasion and/or foci formation. Not surprisingly, this study also demonstrated increased metastatic 22 
potential with tail vein injected murine cells that were transiently knocked down for p53. The main 23 
difference between this study and our study is that we knocked down gain-of-function p53 and not 24 
wild type p53.  The only other in vivo study that demonstrated a role for Mdm2 in metastasis was also 25 
14 
in a wild type p53 background and credited the decreased metastasis on the activation of p53 genes. 1 
Furthermore, the knock down of Mdm2 by RNAi resulted in decreased proliferation and tumor growth, 2 
which also contributed to the decrease in metastasis in these wild type p53 cells.  3 
Our results provide a significant advancement in our understanding of how Mdm2 is regulating 4 
the cellular programs to promote tumor metastasis independent of gain of function mutp53. If mutp53 5 
was driving tumorigenesis, one would expect the MDA468 shMdm2 tumors (which have significantly 6 
more mutp53 than the controls) to be increased in size.  However, these cells grew much slower in 7 
the implanted animals.  Furthermore, when mutp53 was knocked down, the tumors actually had 8 
increased neovascularization than the controls.  Importantly, we show that the animals implanted with 9 
the shp53 cells had higher numbers of CTCs, suggesting that mutp53 is actually a disadvantage in 10 
the early stages of metastasis. However, the abundance of shp53 CTC did not correlate with 11 
increased numbers of metastatic foci, signifying that mutp53 is important for extravasation or other 12 
steps of metastasis. Lastly, knocking-down mutp53 by shRNA in shMdm2 cells did not alter EMT-13 
related responses demonstrating that the effects of Mdm2 knock-down are independent of mutp53 14 
levels (Fig. S3).  Thus, we show there are independent and distinct yet dynamic roles of mutp53 and 15 
Mdm2 during the different phases of metastasis.   16 
A major road block in the ability to treat metastatic disease is delineating the basic signaling 17 
pathways involved in the genesis, survival, drug-resistance, migration, and growth of metastatic cells. 18 
The effectiveness of new therapies will require a comprehensive approach to target multiple 19 
pathways, preferably those that are important before tumor cells reach circulation.  Based on our 20 
work, future drugs should be designed to interrupt the p53 independent functions of Mdm2. 21 
22 
23 
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Figure 1. Silencing of Mdm2 results in decreased levels of EMT markers and mesenchymal 11 
morphology. (a) Knock-down of Mdm2 was confirmed by western blot in MDA468 cells and resulted 12 
in increased p53 levels. Although silencing Mdm2 in TMD231 cells resulted in decreased Mdm2 13 
levels, p53 levels were not affected. (b) SNAI1 levels were also decreased in the shMdm2 cell lines. 14 
(c) SNAI1, Vimentin, and N- cadherin levels were correlated with Mdm2 protein levels while E- 15 
cadherin (an epithelial marker) was inversely correlated with Mdm2 levels in MDA468. TGFß 16 
treatment (for 48 h with normoxia and 72 h with hypoxia) resulted in increased EMT marker levels in 17 
control cells, but not in shMdm2 MDA468 cells. (d) Phase contrast images showing the morphology 18 
of MDA468 cells after 48 h TGFß treatment and with or without hypoxia as indicated. (Scale bar 19 
represents 100 ?m). All panels: shControl = shC; shMdm2= sh2; Norm= 21% oxygen; Hyp = 1% 20 
oxygen. 21 
Figure 2. shMdm2 cells have impaired migration and invasion. (a) Traditional wound healing 22 
assay showing that MDA468 shControl cells (left) were able to close the gap in less time compared to 23 
shMdm2 cells (right). Note: 0 h time points were imaged at 5X; all following time points were imaged 24 
21 
at 10X (Scale bars = 200 ?m). Gap area was measured using a wound healing macro for ImageJ 1 
(bottom panel). (b) mCherry fluorescent shControl TMD231 cells and GFP fluorescent shMdm2 2 
TMD231 cells were plated on coverslips and transferred to a new plate. Migrating cells of each color 3 
were counted in three separate fields of view and averaged.  (c) shControl and shMdm2 cells were 4 
plated in 8 ?m Matrigel chambers and allowed to invade for 22 h using serum as a chemoattractant. 5 
Cells were counted in three random 25X magnification fields and experiments were done in triplicate. 6 
Percent invasion was determined as defined in Materials and Methods. All panels: Error bars 7 
represent ± SEM (n=3). Significances of differences between shControl and shMdm2 values were 8 
determined using unpaired, 2-tailed, student’s t tests (*P<0.05; **P<0.01). 9 
Figure 3. Knock-down of Mdm2 slows tumor growth. (a) Tumor volumes of MDA468 (left panel) 10 
and TMD231 (right panel) shControl orthotopically implanted animals increased faster than that of 11 
shMdm2 implanted mice. (b) The final tumor weights of MDA468 shControl tumors were significantly 12 
greater than those in the shMdm2 orthotopically implanted animals (left panel), while the TMD231 set 13 
was not significantly different (right panel). All panels: Error bars represent ± SEM (n=7). 14 
Significances of differences between shControl (shC) and shMdm2 (sh2) values were determined 15 
using unpaired, 2-tailed, student’s t tests (ns = not significant; ***P<0.001). 16 
Figure 4. Mdm2 is important for angiogenesis. (a) Western blots of cell lysates from cells grown in 17 
either normoxia or hypoxia showing that despite culture conditions, when Mdm2 is knocked down, 18 
HIF1??and VEGF levels are decreased. (b) Representative images of tumor sections stained brown 19 
with CD31 (PECAM-1). The percentages of immature vessels in tumors of both shMdm2 cell lines 20 
were significantly lower compared to the respective shControl tumors. The percentages in shp53 21 
tumors, on the other hand, were significantly higher than the shControl tumors. (Scale bar = 100 ?m). 22 
(c) HIF1??and VEGF levels were lower in the shMdm2 tumors compared to shControl tumors as23 
assessed by western blot analysis. All panels: shControl = shC; shMdm2= sh2; Norm= 21% oxygen; 24 
22 
Hyp = 1% oxygen. Error bars represent ± SEM (n=7). Significances of differences were determined 1 
using unpaired, 2-tailed, student’s t tests (*P<0.05; **P<0.01; ***P<0.001). 2 
Figure 5. Mdm2 is ultimately critical for metastasis. (a) Western blots showing that EMT markers 3 
and MMP2 are higher in lysates from shControl tumors compared to shMdm2 tumors. E- cadherin 4 
and p53 are more abundant in shMdm2 MDA468 tumors compared to shControl tumors. (b) FACs 5 
analysis using human-specific EGFR revealed that there was less shMdm2 and more shp53 CTC 6 
compared to the respective controls. (c) H&E stained lung sections (left) demonstrating decreased 7 
metastasis with the shMdm2 implanted mice compared to those implanted with shControl cells. Only 8 
the foci composed of greater than 25 cells were counted for the TMD231 shControl and shp53 9 
implanted animals. All panels: shControl = shC; shMdm2= sh2. Error bars represent ± SEM (n=7). 10 
Significances of differences were determined using unpaired, 2-tailed, student’s t tests (ns= not 11 
significant; *P<0.05; **P<0.01; ***P<0.001). 12 
Figure 6. Mdm2 and p53 impact metastasis in distinct ways. Schematic representing major steps 13 
of metastasis and the involvement of Mdm2. 14 
15 
16 






